AUROPHARMA Aurobindo Pharma Q2 FY26 results (Jul–Sep 2025) and concall
Aurobindo Pharma delivered a solid Q2 FY26, marked by 6% YoY revenue growth and 7% YoY EBITDA growth, driven by strong performance in US Formulations and Europe. The company is actively advancing its Pen-G plant operations and a robust biosimilar pipeline, with multiple filings and launches anticipated. While challenges remain in the US Injectable segment and initial losses in the China OSD facility, management expressed confidence in achieving its FY26 margin target of 20-21% and leveraging strategic investments for future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 6.3%, net profit up 3.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 +6% |
| EBITDA | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 +7% |
| Net profit | 817 | 846 | 903 | 824 | 848 +4% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
